+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Effect of switching to risperidone after unsuccessful treatment with aripiprazole on plasma monoamine metabolites level in the treatment of acute schizophrenia

Effect of switching to risperidone after unsuccessful treatment with aripiprazole on plasma monoamine metabolites level in the treatment of acute schizophrenia

Human Psychopharmacology 27(5): 517-520

In the treatment of acute schizophrenia, risperidone and aripiprazole are both placed the first line antipsychotics. These two antipsychotics have different pharmacological effects. We investigated the effects of risperidone on plasma levels of homovanillic acid (HVA) and 3-methoxy-4hydroxyphenylglycol after unsuccessful aripiprazole treatment in acute schizophrenia. Ten Japanese patients with acute schizophrenia were enrolled to this study. Plasma levels of monoamine metabolites were analyzed with high-performance liquid chromatography with electrochemical detection. Risperidone improved the symptoms and 4 of 10 patients were responders. Risperidone showed a tendency to decrease plasma HVA (pHVA) levels in responders (p = 0.068), but not in non-responders (p = 1.0). At baseline, pHVA levels of responders were significantly higher than that of non-responders (p = 0.033). A trend for negative correlation was found between pHVA at baseline and the changes in Positive and Negative Syndrome Scale-Total (p = 0.061, r = -0.61). Our results suggest that high pHVA level before switching may predict good response to the second line antipsychotics after unsuccessful first antipsychotic treatment. If aripiprazole is not effective in acute schizophrenia, switching to risperidone may be effective and reasonable strategy for improving symptoms.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 036552282

Download citation: RISBibTeXText

PMID: 22927115

DOI: 10.1002/hup.2251

Related references

Switching antipsychotics to aripiprazole or blonanserin and plasma monoamine metabolites levels in patients with schizophrenia. Human Psychopharmacology 29(2): 199-202, 2014

Effects of aripiprazole and the Taq1A polymorphism in the dopamine D2 receptor gene on the clinical response and plasma monoamine metabolites level during the acute phase of schizophrenia. Journal of Clinical Psychopharmacology 32(1): 106-109, 2012

Switching to risperidone after unsuccessful treatment of olanzapine in the first-episode schizophrenia: an open trial. Progress in Neuro-Psychopharmacology and Biological Psychiatry 30(6): 1067-1072, 2006

Switching to olanzapine after unsuccessful treatment with risperidone during the first episode of schizophrenia: an open-label trial. Journal of Clinical Psychiatry 67(10): 1577-1582, 2006

Treatment of Paroxysmal Perceptual Alteration in Catatonic Schizophrenia by Switching to Aripiprazole from Risperidone: A Case Report. Clinical Schizophrenia and Related Psychoses 10(1): 37-40, 2016

A Randomized Comparison of Aripiprazole and Risperidone for the Acute Treatment of First-Episode Schizophrenia and Related Disorders: 3-Month Outcomes. Schizophrenia Bulletin 41(6): 1227-1236, 2016

Haloperidol, olanzapine and risperidone reduce treatment failure compared to aripiprazole, quetiapine and ziprasidone in acute schizophrenia. Evidence-Based Mental Health 10(3): 76, 2007

Efficacy and safety of aripiprazole in the acute treatment of schizophrenia in Chinese patients with risperidone as an active control: a randomized trial. Journal of Clinical Psychiatry 68(1): 29-36, 2007

Abnormal plasma monoamine metabolism in schizophrenia and its correlation with clinical responses to risperidone treatment. Psychiatry Research 188(2): 197-202, 2011

Psychosis associated with switching from risperidone to aripiprazole in an adolescent on methylphenidate treatment. Progress in Neuro-Psychopharmacology and Biological Psychiatry 35(2): 648-649, 2011

The effect of long-acting paliperidone palmitate once-monthly on negative and depressive symptoms in patients with schizophrenia switched from previous unsuccessful treatment with oral aripiprazole. Therapeutic Advances in Psychopharmacology 7(2): 59-65, 2017

The changes of plasma monoamine metabolites levels after antipsychotic drug treatment in patients with schizophrenia. 2007

The neurocognitive effects of aripiprazole compared with risperidone in the treatment of schizophrenia. Hiroshima Journal of Medical Sciences 61(4): 75-83, 2013

P.3.d.015 Prolactin levels in schizophrenia patients treated with paliperidone switching from risperidone, aripiprazole and olanzapine. European Neuropsychopharmacology 24: S529-S530, 2014

Balancing Potential Risks and Benefits of Adjunctive Use of Aripiprazole With Risperidone for the Treatment of Schizophrenia. Journal of Clinical Psychopharmacology 31(1): 136-137, 2011